U.S. Pharma Stock News

NYSE:CLVT
NYSE:CLVTProfessional Services

Clarivate Claude Tie Up Tests AI Disintermediation And Workflow Stickiness

Clarivate (NYSE:CLVT) has integrated its regulatory intelligence with Anthropic's Claude AI assistant. The collaboration embeds Clarivate's regulatory data directly into biopharma, biotech, and medtech AI workflows. The move is aimed at supporting regulatory affairs teams by keeping trusted data closer to day to day decision making. Clarivate focuses on data, analytics, and workflow tools for research driven industries, and life sciences is a core part of that mix. By plugging its...
NYSE:CNH
NYSE:CNHMachinery

CNH Industrial Eyes Stickier Revenue With New Antenna And Dealer Expansion

Hemisphere GNSS, a brand of CNH Industrial, has introduced the A65 GNSS antenna in partnership with Calian Group, targeting better interference rejection and easier upgrades for precision agriculture systems. Forrester Farm Equipment is acquiring AG-Industrial, expanding the CNH dealer network and deepening cooperation on parts and service support across North America. CNH Industrial (NYSE:CNH), trading at about $10.65, has a mixed recent performance, with a 13.9% return year to date but...
NasdaqGS:XRAY
NasdaqGS:XRAYMedical Equipment

DENTSPLY SIRONA Bets On Dental MRI To Reframe Growth Story

DENTSPLY SIRONA (NasdaqGS:XRAY) and Siemens Healthineers secured FDA clearance for the MAGNETOM Free.Max Dental Edition, described as the first MRI system dedicated to dental use. The company is preparing for a US launch, supported by clinical trial data and upcoming training programs for dental professionals. The system is designed to offer high contrast, non ionizing imaging for applications such as endodontics and TMJ assessment. At a current share price of $11.54, DENTSPLY SIRONA comes...
NYSE:HNGE
NYSE:HNGEHealthcare

Is It Time To Reassess Hinge Health (HNGE) After Its Recent Share Price Rebound?

If you are wondering whether Hinge Health is attractively priced or already baking in a lot of optimism, this article is designed to help you frame that question clearly. The stock last closed at US$45.00, with a 16.1% gain over the past 30 days, but a 2.5% decline over the last week and a 1.2% decline year to date. This hints at shifting views on both its potential and its risks. Recent news coverage has focused on Hinge Health's position as a listed musculoskeletal care company, along with...
NasdaqGS:ROCK
NasdaqGS:ROCKBuilding

Is Gibraltar Industries (ROCK) Now A Potential Opportunity After A 36.9% One Year Share Price Drop

Wondering whether Gibraltar Industries is starting to look like value at today’s price, or if the stock’s risks still outweigh the potential upside? This article is built to help you weigh that up using clear valuation checks. After closing at US$41.27, the stock has seen a 2.6% gain over the last 7 days. That sits against a 23.7% decline over 30 days and a 36.9% decline over the past year, with returns of 17.7% decline year to date, 11.2% decline over 3 years and 52.7% decline over 5...
NasdaqGS:TTAN
NasdaqGS:TTANSoftware

ServiceTitan (TTAN) Revenue Growth Of 26.5% Tests Bearish Profitability Narratives

ServiceTitan (TTAN) just posted another quarter of rapid top line expansion, with Q3 FY 2026 revenue at US$249.2 million and a basic EPS loss of US$0.42, against a backdrop of 26.5% revenue growth over the past year and a trailing twelve month net loss of US$298.1 million. The company has seen quarterly revenue move from US$192.9 million in Q2 FY 2025 to US$249.2 million in Q3 FY 2026. Over the same period, basic EPS losses ranged from US$1.43 in Q2 FY 2025 to US$0.42 in the latest quarter,...
NasdaqGS:LI
NasdaqGS:LIAuto

Has Li Auto (NasdaqGS:LI) Fallen Too Far After Recent 36.9% Share Price Slide

If you are wondering whether Li Auto's current share price still reflects its long term potential, you are not alone. Many investors are asking what the stock is really worth right now. The stock closed at US$17.33, with returns of 1.0% over 7 days, a 9.7% decline over 30 days, roughly flat year to date at 0.5%, and a 36.9% decline over the last year, which has shifted how some investors may be thinking about both upside potential and risk. Recent news flow around Li Auto has focused on...
NYSE:PFGC
NYSE:PFGCConsumer Retailing

Performance Food Group Faces New Questions With Cheney Brothers US$42.5m Expansion

Cheney Brothers, a subsidiary of Performance Food Group, plans a $42.5 million expansion of its South Carolina distribution center. The project is expected to add new jobs in the region and support the integration of a recent acquisition. The expansion reflects Performance Food Group's focus on building out its distribution network and operational footprint. Performance Food Group (NYSE:PFGC) is drawing attention with this fresh capital commitment alongside a current share price of $88.18...
NYSE:ABX
NYSE:ABXInsurance

Abacus Global Management (ABX) Profitability Turn Reinforces Bullish Narrative Despite Valuation Tension

Abacus Global Management (ABX) has just wrapped up FY 2025 with fourth quarter revenue of US$71.9 million and basic EPS of US$0.07, rounding out a trailing twelve month EPS of US$0.38 on revenue of US$235.2 million. The company has seen quarterly revenue move from US$33.2 million and basic EPS of a loss of US$0.22 in Q4 2024 to US$71.9 million and EPS of US$0.07 in Q4 2025, while trailing twelve month net income shifted from a loss of US$24.0 million to a profit of US$36.5 million. This sets...
NYSE:AIN
NYSE:AINMachinery

Albany International’s 2026 World Engineering Day Role And Dividend Question

Albany International (NYSE:AIN) has been named an official partner for World Engineering Day for Sustainable Development 2026. The partnership spotlights the company’s role in materials science for sustainability and raises its profile with global engineering and policy audiences. For investors watching Albany International at a share price of $53.57, this new partnership adds a fresh layer of visibility that does not show up directly in recent price moves. The stock has seen a 26.3%...
NasdaqGS:BSY
NasdaqGS:BSYSoftware

Is It Time To Reassess Bentley Systems (BSY) After Recent Share Price Swings?

If you are wondering whether Bentley Systems is currently priced attractively or if the share price already reflects its quality, this article explains what the current valuation suggests. The stock last closed at US$38.19, with recent returns showing a 4.0% decline over 7 days, a 12.6% gain over 30 days, and results that are roughly flat year to date and lower over 1 and 3 years. Recent coverage has focused on how investors are reassessing software names as interest rates, infrastructure...
NYSE:DKS
NYSE:DKSSpecialty Retail

Has DICK'S Sporting Goods (DKS) Run Too Far After Its Strong Multi‑Year Share Price Gains

If you are wondering whether DICK'S Sporting Goods is reasonably priced or getting ahead of itself, this article will walk through how its current share price stacks up against several valuation checks. The stock last closed at US$192.16, with returns of 1.1% over the past year, 42.0% over 3 years and 175.9% over 5 years. Shorter term moves have been softer, with a 2.6% decline over 7 days, 6.0% decline over 30 days and 4.0% decline year to date. Recent attention on DICK'S Sporting Goods has...
NasdaqGS:MRCY
NasdaqGS:MRCYAerospace & Defense

Mercury Systems Acquisition Brings Critical Manufacturing In House For Defense Programs

Mercury Systems (NasdaqGS:MRCY) has acquired SolderMask, Inc., adding specialized manufacturing capabilities and intellectual property. The deal brings in skilled personnel and assets that directly support more than 20 active Mercury programs tied to critical defense work. The acquisition is intended to accelerate production efficiency and strengthen delivery commitments across key customer contracts. Mercury Systems, trading at $78.16, has seen a 68.0% return over the past year and a 69.1%...
NYSE:PIPR
NYSE:PIPRCapital Markets

Assessing Piper Sandler (PIPR) After Recent Share Price Weakness And Capital Markets Activity

If you are wondering whether Piper Sandler Companies' current share price really reflects its underlying worth, or if the recent run leaves room for value, this article walks through that question step by step. The stock last closed at US$282.30, with returns showing a 3.8% decline over 7 days, a 17.4% decline over 30 days, a 19.3% decline year to date, a 14.2% gain over 1 year and a very large 3 year and 5 year return. Recent coverage around Piper Sandler Companies has focused on its role...
NasdaqGM:LFMD
NasdaqGM:LFMDHealthcare Services

LifeMD (LFMD) Is Up 32.7% After Returning To Profitability And Expanding GLP‑1 Telehealth Offerings

In early March 2026, LifeMD, Inc. reported that it moved from a US$21.41 million annual net loss in 2024 to US$14.35 million net income in 2025, issued double‑digit revenue growth guidance for 2026, and highlighted expanding telehealth offerings including its oral Wegovy weight management launch with Novo Nordisk. This shift to profitability, combined with more than 322,000 active subscribers and growing GLP‑1 and women’s health programs, signals a business model that is scaling across...
NasdaqGS:MAPS
NasdaqGS:MAPSSoftware

WM Technology (MAPS) Margin Compression To 1.1% Tests Bullish Earnings Narratives

WM Technology (MAPS) closed out FY 2025 with Q4 revenue of about US$43.1 million and a basic EPS loss of roughly US$0.03, while trailing twelve month EPS stood at around US$0.02 on revenue of roughly US$174.7 million. Over recent periods the company has seen quarterly revenue range between about US$42.2 million and US$47.7 million, with EPS moving from a profit of roughly US$0.03 per share in late 2024 to small profits through most of 2025 before the latest quarterly loss. This has left...
NYSE:MC
NYSE:MCCapital Markets

Is It Time To Revisit Moelis (MC) After The Recent Share Price Slump

If you are wondering whether Moelis shares offer good value at today's price, it helps to step back and look at what the current market is implying about the business. The stock last closed at US$51.75, after a 7.8% decline over the past week, a 25.1% decline over the past month, and a 27.3% decline year to date, while still showing a 51.6% return over 3 years and 23.6% over 5 years. These recent moves have kept Moelis on investors' radars, with market commentary often linking advisory firms...
NasdaqCM:IMUX
NasdaqCM:IMUXBiotechs

Should Extended European Patent Protection for Vidofludimus Calcium Reshape Immunic’s (IMUX) Long-Term Value Proposition?

Immunic, Inc. recently secured a key European patent for its lead asset vidofludimus calcium, aligning protection with existing U.S. coverage and potentially extending exclusivity into the 2040s for chronic inflammatory and autoimmune indications. This expanded intellectual property protection materially underpins the company’s core therapeutic franchise by lengthening its runway to develop and, if approved, commercialize its main clinical asset. Against this backdrop, we’ll explore how the...
NasdaqCM:DTIL
NasdaqCM:DTILBiotechs

Precision BioSciences (DTIL) Q4 Profit Of US$19.2m Challenges Ongoing Loss Narrative

Precision BioSciences (DTIL) closed out FY 2025 with Q4 revenue of US$34.2 million and Basic EPS of US$1.01, alongside earnings from discontinued operations of US$0.9 million and net income excluding extra items of US$19.2 million. Over recent quarters, the company has seen revenue range from US$0.6 million in Q4 2024 to US$34.2 million in Q4 2025. Over the same period, quarterly Basic EPS has moved from a loss of US$2.22 in Q4 2024 to a profit of US$1.01 in Q4 2025. This sets up an earnings...
NYSE:TIC
NYSE:TICProfessional Services

TIC Solutions CEO Change And US$200m Buyback Reframe Turnaround Story

TIC Solutions (NYSE:TIC) has appointed Ben Heraud as its new CEO, succeeding long-serving leader Tal Pizzey. The company has also launched a $200 million share repurchase program. These changes were recently announced and have not been widely discussed in prior coverage. TIC Solutions is making these moves at a time when its share price is $7.25, with the stock showing a 40.3% decline over the past year and a 26.7% decline year to date. The new leadership and buyback plan arrive against...
NasdaqGS:EVCM
NasdaqGS:EVCMSoftware

EverCommerce (EVCM) Profitability Milestone Tests Bullish Narratives On Margin Sustainability

EverCommerce (EVCM) has wrapped up FY 2025 with fourth quarter revenue of US$151.2 million and basic EPS of US$0.03, alongside net income from ongoing operations of US$5.7 million. This caps a trailing twelve month period with revenue of US$588.9 million and EPS of US$0.10. Over recent quarters the company has seen revenue range from US$142.3 million to US$151.2 million, with quarterly EPS between US$0.01 and US$0.03. Over the same period, trailing twelve month net income from ongoing...
NYSE:FVRR
NYSE:FVRRProfessional Services

Is Fiverr (FVRR) Pricing Reflect Recent Share Slump Accurately

If you are wondering whether Fiverr International's current share price reflects its true worth, you are not alone. This article will walk you through what the numbers are actually saying about value. The stock has seen sizeable declines recently, with a 7.7% fall over the last week, a 27.6% decline over the last month, a 46.8% drop year to date, and a 59.2% decline over the past year. This extends a 68.5% and 95.3% fall across the last 3 and 5 years respectively. Recent attention on Fiverr...
OTCPK:BUKS
OTCPK:BUKSAerospace & Defense

Butler National (OTCPK:BUKS) Margin Expansion Reinforces Bullish Earnings Narratives In Q3 2026

Butler National (BUKS) has reported Q3 2026 revenue of US$26.9 million and basic EPS of US$0.10, set against trailing twelve month revenue of US$91.9 million and EPS of US$0.30 that came with 44.1% earnings growth and a 21.4% net margin over the past year. The company has seen quarterly revenue move from US$21.2 million in Q3 2025 to US$26.9 million in Q3 2026 and basic EPS from US$0.05 to US$0.10 across the same periods, with trailing net income reaching US$19.7 million, which positions the...
NasdaqGS:TNYA
NasdaqGS:TNYABiotechs

How TN-301 Progress And Alnylam Deal At Tenaya Therapeutics (TNYA) Has Changed Its Investment Story

In early March 2026, Tenaya Therapeutics reported a narrower full-year 2025 net loss of US$90.6 million and highlighted new preclinical data for TN-301 in Duchenne muscular dystrophy alongside a research collaboration with Alnylam Pharmaceuticals on up to 15 cardiovascular gene targets that could yield as much as US$1.13 billion in milestones. Together, these updates underscore how Tenaya is pairing emerging HDAC6 science in DMD and heart failure with a genetically guided partnership model...